LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 41

Search options

  1. Article: The Current Status and Future Perspectives of Beta-Lactam Therapeutic Drug Monitoring in Critically Ill Patients.

    Novy, Emmanuel / Martinière, Hugo / Roger, Claire

    Antibiotics (Basel, Switzerland)

    2023  Volume 12, Issue 4

    Abstract: Beta-lactams (BL) are the first line agents for the antibiotic management of critically ill patients with sepsis or septic shock. BL are hydrophilic antibiotics particularly subject to unpredictable concentrations in the context of critical illness ... ...

    Abstract Beta-lactams (BL) are the first line agents for the antibiotic management of critically ill patients with sepsis or septic shock. BL are hydrophilic antibiotics particularly subject to unpredictable concentrations in the context of critical illness because of pharmacokinetic (PK) and pharmacodynamics (PD) alterations. Thus, during the last decade, the literature focusing on the interest of BL therapeutic drug monitoring (TDM) in the intensive care unit (ICU) setting has been exponential. Moreover, recent guidelines strongly encourage to optimize BL therapy using a PK/PD approach with TDM. Unfortunately, several barriers exist regarding TDM access and interpretation. Consequently, adherence to routine TDM in ICU remains quite low. Lastly, recent clinical studies failed to demonstrate any improvement in mortality with the use of TDM in ICU patients. This review will first aim at explaining the value and complexity of the TDM process when translating it to critically ill patient bedside management, interpretating the results of clinical studies and discussion of the points which need to be addressed before conducting further TDM studies on clinical outcomes. In a second time, this review will focus on the future aspects of TDM integrating toxicodynamics, model informed precision dosing (MIPD) and "at risk" ICU populations that deserve further investigations to demonstrate positive clinical outcomes.
    Language English
    Publishing date 2023-03-30
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2681345-2
    ISSN 2079-6382
    ISSN 2079-6382
    DOI 10.3390/antibiotics12040681
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Interest of a metabolic approach using the calScreener™ technology to detect Candida in the peritoneal fluid: A pilot study.

    Novy, Emmanuel / Collot, Marie / Chevallier, Paul / Cunat, Lisiane / Machouart, Marie

    Journal de mycologie medicale

    2023  Volume 33, Issue 4, Page(s) 101418

    MeSH term(s) Candida ; Ascitic Fluid ; Pilot Projects
    Language English
    Publishing date 2023-08-01
    Publishing country France
    Document type Letter
    ZDB-ID 1067006-3
    ISSN 1773-0449 ; 1156-5233
    ISSN (online) 1773-0449
    ISSN 1156-5233
    DOI 10.1016/j.mycmed.2023.101418
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: When to start vasopressin in septic shock: the strategy we propose.

    Guerci, Philippe / Belveyre, Thibaut / Mongardon, Nicolas / Novy, Emmanuel

    Critical care (London, England)

    2022  Volume 26, Issue 1, Page(s) 125

    MeSH term(s) Humans ; Norepinephrine ; Shock, Septic/drug therapy ; Vasoconstrictor Agents/pharmacology ; Vasoconstrictor Agents/therapeutic use ; Vasopressins/therapeutic use
    Chemical Substances Vasoconstrictor Agents ; Vasopressins (11000-17-2) ; Norepinephrine (X4W3ENH1CV)
    Language English
    Publishing date 2022-05-06
    Publishing country England
    Document type Letter
    ZDB-ID 2041406-7
    ISSN 1466-609X ; 1364-8535
    ISSN (online) 1466-609X
    ISSN 1364-8535
    DOI 10.1186/s13054-022-04001-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Pharmacokinetic and pharmacodynamic considerations for antifungal therapy optimisation in the treatment of intra-abdominal candidiasis.

    Novy, Emmanuel / Roger, Claire / Roberts, Jason A / Cotta, Menino Osbert

    Critical care (London, England)

    2023  Volume 27, Issue 1, Page(s) 449

    Abstract: Intra-abdominal candidiasis (IAC) is one of the most common of invasive candidiasis observed in critically ill patients. It is associated with high mortality, with up to 50% of deaths attributable to delays in source control and/or the introduction of ... ...

    Abstract Intra-abdominal candidiasis (IAC) is one of the most common of invasive candidiasis observed in critically ill patients. It is associated with high mortality, with up to 50% of deaths attributable to delays in source control and/or the introduction of antifungal therapy. Currently, there is no comprehensive guidance on optimising antifungal dosing in the treatment of IAC among the critically ill. However, this form of abdominal sepsis presents specific pharmacokinetic (PK) alterations and pharmacodynamic (PD) challenges that risk suboptimal antifungal exposure at the site of infection in critically ill patients. This review aims to describe the peculiarities of IAC from both PK and PD perspectives, advocating an individualized approach to antifungal dosing. Additionally, all current PK/PD studies relating to IAC are reviewed in terms of strength and limitations, so that core elements for the basis of future research can be provided.
    MeSH term(s) Humans ; Antifungal Agents/therapeutic use ; Antifungal Agents/pharmacokinetics ; Critical Illness/therapy ; Candidiasis, Invasive/drug therapy ; Abdominal Cavity ; Intraabdominal Infections/drug therapy
    Chemical Substances Antifungal Agents
    Language English
    Publishing date 2023-11-20
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2041406-7
    ISSN 1466-609X ; 1364-8535
    ISSN (online) 1466-609X
    ISSN 1364-8535
    DOI 10.1186/s13054-023-04742-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Population pharmacokinetics of prophylactic cefoxitin in elective bariatric surgery patients: A prospective monocentric study.

    Novy, Emmanuel / Liu, Xin / Hernandez-Mitre, Maria Patricia / Belveyre, Thibaut / Scala-Bertola, Julien / A Roberts, Jason / L Parker, Suzanne

    Anaesthesia, critical care & pain medicine

    2024  , Page(s) 101376

    Abstract: Background: This study describes the population pharmacokinetics of cefoxitin in obese patients undergoing elective bariatric surgery and evaluates different dosing regimens for achievement of pre-defined target exposures.: Methods: Serial blood ... ...

    Abstract Background: This study describes the population pharmacokinetics of cefoxitin in obese patients undergoing elective bariatric surgery and evaluates different dosing regimens for achievement of pre-defined target exposures.
    Methods: Serial blood samples were collected during surgery with relevant clinical data. Total serum cefoxitin concentrations were measured by chromatographic assay and analysed using a population PK approach with Pmetrics®. The cefoxitin unbound fraction (fu) was estimated. Dosing simulations were performed to ascertain the probability of target attainment (PTA) to achieve cefoxitin fu above minimum inhibitory concentrations (MIC) from surgical incision to wound closure. Fractional target attainment (FTA) was calculated against MIC distributions of common pathogens.
    Results: A total of 123 obese patients (median BMI 44.3 kg/m
    Conclusion: Intermittent dosing regimens resulted in optimal FTAs against susceptible MIC distributions of S. aureus and E. coli when simulating with 50% cefoxitin protein binding. Continuous infusion of cefoxitin may improve FTA regardless of protein binding.
    Study registration: Registration on ClinicalTrials.gov, NCT03306290.
    Language English
    Publishing date 2024-03-15
    Publishing country France
    Document type Journal Article
    ISSN 2352-5568
    ISSN (online) 2352-5568
    DOI 10.1016/j.accpm.2024.101376
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Is therapeutic drug monitoring really helpful for managing piperacillin/tazobactam therapy in critically ill patients?

    Novy, Emmanuel / François, Thomas / Luc, Amandine / Pape, Elise / Scala-Bertola, Julien

    Intensive care medicine

    2022  Volume 48, Issue 11, Page(s) 1676–1678

    MeSH term(s) Humans ; Critical Illness/therapy ; Drug Monitoring ; Piperacillin, Tazobactam Drug Combination/therapeutic use ; Piperacillin/therapeutic use ; Anti-Bacterial Agents/therapeutic use ; Penicillanic Acid/therapeutic use
    Chemical Substances Piperacillin, Tazobactam Drug Combination (157044-21-8) ; Piperacillin (X00B0D5O0E) ; Anti-Bacterial Agents ; Penicillanic Acid (87-53-6)
    Language English
    Publishing date 2022-08-09
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 80387-x
    ISSN 1432-1238 ; 0340-0964 ; 0342-4642 ; 0935-1701
    ISSN (online) 1432-1238
    ISSN 0340-0964 ; 0342-4642 ; 0935-1701
    DOI 10.1007/s00134-022-06830-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Algorithm for rational use of Film Array Pneumonia Panel in bacterial coinfections of critically ill ventilated COVID-19 patients.

    Novy, Emmanuel / Goury, Antoine / Thivilier, Carine / Guillard, Thomas / Alauzet, Corentine

    Diagnostic microbiology and infectious disease

    2021  Volume 101, Issue 3, Page(s) 115507

    Abstract: The FilmArray Pneumonia Panel has proven to be an effective tool for rapid detection of main respiratory pathogens. However, its rational use needs appropriate knowledge and formation regarding its indication and interpretation. Herein, we provide some ... ...

    Abstract The FilmArray Pneumonia Panel has proven to be an effective tool for rapid detection of main respiratory pathogens. However, its rational use needs appropriate knowledge and formation regarding its indication and interpretation. Herein, we provide some advices to help with success of its daily routine use, particularly in critically ill ventilated COVID-19 patients. Clinical Trial registration number: NCT04453540.
    MeSH term(s) Algorithms ; COVID-19/complications ; Coinfection/diagnosis ; Critical Illness ; Humans ; Molecular Diagnostic Techniques/methods ; Pneumonia, Bacterial/complications ; Pneumonia, Bacterial/diagnosis ; Pneumonia, Bacterial/microbiology ; Respiration, Artificial ; SARS-CoV-2
    Language English
    Publishing date 2021-07-23
    Publishing country United States
    Document type Journal Article
    ZDB-ID 604920-5
    ISSN 1879-0070 ; 0732-8893
    ISSN (online) 1879-0070
    ISSN 0732-8893
    DOI 10.1016/j.diagmicrobio.2021.115507
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Reappraisal of intra-abdominal candidiasis: insights from peritoneal fluid analysis.

    Novy, Emmanuel / Esposito, Mathieu / Birckener, Julien / Germain, Adeline / Losser, Marie-Reine / Machouart, Marie-Claire / Guerci, Philippe

    Intensive care medicine experimental

    2023  Volume 11, Issue 1, Page(s) 67

    Abstract: Background: The understanding of high mortality associated with intra-abdominal candidiasis (IAC) remains limited. While Candida is considered a harmless colonizer in the digestive tract, its role as a true pathogen in IAC is still debated. Evidence ... ...

    Abstract Background: The understanding of high mortality associated with intra-abdominal candidiasis (IAC) remains limited. While Candida is considered a harmless colonizer in the digestive tract, its role as a true pathogen in IAC is still debated. Evidence regarding Candida virulence in the human peritoneal fluid are lacking. We hypothesized that during IAC, Candida albicans develops virulence factors to survive to new environmental conditions. The objective of this observational exploratory monocentric study is to investigate the influence of peritoneal fluid (PF) on the expression of C. albicans virulence using a multimodal approach.
    Materials and methods: A standardized inoculum of a C. albicans (3.10
    Results: A total of 26 PF samples from patients with secondary peritonitis were included in the study. Critically ill patients were mostly male (73%) with a median age of 58 years admitted for urgent surgery (78%). Peritonitis was mostly hospital-acquired (81%), including 13 post-operative peritonitis (50%). The infected PF samples predominantly exhibited polymicrobial composition. The findings revealed substantial variability in C. albicans growth and morphological changes in the PF compared to ascitic fluid. Virulence gene expression and metabolic production were dependent on the specific PF sample and the presence of bacterial coinfection.
    Conclusions: This study provides evidence of C. albicans virulence expression in the peritoneal fluid. The observed variability in virulence expression suggests that it is influenced by the composition of PF and the presence of bacterial coinfection. These findings contribute to a better understanding of the complex dynamics of intra-abdominal candidiasis and advocate for personalized approach for IAC patients. Trial registration https://clinicaltrials.gov/ (NCT05264571; February 22, 2022).
    Language English
    Publishing date 2023-09-30
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 2740385-3
    ISSN 2197-425X
    ISSN 2197-425X
    DOI 10.1186/s40635-023-00552-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: In vitro stability study of 10 beta-lactam antibiotics in human plasma samples.

    Brenkman, Matthieu / Cartau, Tom / Pape, Elise / Kolodziej, Allan / Charmillon, Alexandre / Novy, Emmanuel / Jouzeau, Jean-Yves / Gambier, Nicolas / Scala-Bertola, Julien

    Fundamental & clinical pharmacology

    2023  

    Abstract: Background and objectives: Beta-lactam antibiotics are reported for some of them to be subject to a rapid degradation in infusion solutions and in human blood samples. However, the current data of stability available in blood samples are limited to a ... ...

    Abstract Background and objectives: Beta-lactam antibiotics are reported for some of them to be subject to a rapid degradation in infusion solutions and in human blood samples. However, the current data of stability available in blood samples are limited to a few number of beta-lactam antibiotics, and the methodology of the corresponding studies may be discussed. The objective of the present study is to evaluate the stability of 10 beta-lactam antibiotics in human plasma samples.
    Methods: Stability of amoxicillin, cefazolin, cefepime, cefotaxime, cefoxitin, ceftazidime, ceftriaxone, imipenem, meropenem, and piperacillin was evaluated at low and high concentrations at 20°C, 4°C, -20°C, and -80°C for 1, 7, 60, and 90 days, respectively.
    Results: Amoxicillin, cefepime, meropenem, and piperacillin were the least stable antibiotics. The maximum durations allowing the stability for all the evaluated beta-lactams at both tested concentrations were estimated at 3 h, 23 h, 10 days, and 35 days at 20°C, 4°C, -20°C, and -80°C, respectively.
    Conclusion: We recommend to transport antibiotic plasma samples in ice at 4°C and even at -20°C if these samples come from external hospitals. Ideally, plasma samples should be stored at -80°C if possible; if not, the analysis of the samples should be performed as soon as possible in the limit of 10 days after a storage at -20°C.
    Language English
    Publishing date 2023-11-20
    Publishing country England
    Document type Journal Article
    ZDB-ID 639134-5
    ISSN 1472-8206 ; 0767-3981
    ISSN (online) 1472-8206
    ISSN 0767-3981
    DOI 10.1111/fcp.12969
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Preliminary therapeutic drug monitoring data of β-lactams in critically ill patients with SARS-CoV-2 infection.

    Novy, Emmanuel / Scala-Bertola, Julien / Roger, Claire / Guerci, Philippe

    Anaesthesia, critical care & pain medicine

    2020  Volume 39, Issue 3, Page(s) 387–388

    MeSH term(s) Aged ; Anti-Bacterial Agents/adverse effects ; Anti-Bacterial Agents/blood ; Anti-Bacterial Agents/pharmacokinetics ; Anti-Bacterial Agents/therapeutic use ; Antibiotic Prophylaxis/adverse effects ; Betacoronavirus ; COVID-19 ; Cefepime/adverse effects ; Cefepime/blood ; Coinfection/prevention & control ; Confusion/chemically induced ; Confusion/etiology ; Coronavirus Infections/complications ; Coronavirus Infections/therapy ; Critical Illness/therapy ; Cross Infection/prevention & control ; Deep Sedation ; Delirium/chemically induced ; Delirium/etiology ; Drug Monitoring ; Female ; Humans ; Hypnotics and Sedatives/therapeutic use ; Male ; Middle Aged ; Pandemics ; Pneumonia, Ventilator-Associated/prevention & control ; Pneumonia, Viral/complications ; Pneumonia, Viral/therapy ; Respiration, Artificial/adverse effects ; SARS-CoV-2 ; Sepsis/prevention & control ; beta-Lactams/adverse effects ; beta-Lactams/blood ; beta-Lactams/pharmacokinetics ; beta-Lactams/therapeutic use
    Chemical Substances Anti-Bacterial Agents ; Hypnotics and Sedatives ; beta-Lactams ; Cefepime (807PW4VQE3)
    Keywords covid19
    Language English
    Publishing date 2020-04-18
    Publishing country France
    Document type Letter
    ISSN 2352-5568
    ISSN (online) 2352-5568
    DOI 10.1016/j.accpm.2020.04.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top